Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

David Hodgson, Mahmood Aminilari, Donna Liao, Xiang Y Ye, Ur Metser, Michael Crump, John Kuruvilla, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Richard Tsang, Sita D. Bhella, Danielle Rodin, Anca Prica

Blood (2023) 142 (Supplement 1): 988.

https://doi.org/10.1182/blood-2023-190983

Published: 2023

Journal Articles

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Anca Prica, Tiana Coley, Rachel Aitken, Abi Vijenthira, Manjula Maganti, Samantha J Mayo, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen

Blood (2023) 142 (Supplement 1): 3768.

https://doi.org/10.1182/blood-2023-189154

Published: 2023

Journal Articles

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Samantha J Mayo, Kim Edelstein, Lori Bernstein, Tiana Coley, Stacey Morrison, Abi Vijenthira, Manjula Maganti, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen, Anca Prica

Blood (2023) 142 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2023-190650

Published: 2023

Journal Articles

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Anup J Devasia, Sahar Khan, Eshetu Atenafu, Harjot Vohra, Frédéric Larose, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Christina Zeglinski, Zubaida Mohamed, Christine Chen

Blood (2023) 142 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2023-190310

Published: 2023

Journal Articles

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Sahar Khan, Salman Basrai, Donna Reece, Sita D. Bhella, Vishal Kukreti, Anca Prica, A. Keith Stewart, Suzanne Trudel, Harjot Vohra, Chloe Yang, Sagi Abelson, Christine Chen

Blood (2023) 142 (Supplement 1): 760.

https://doi.org/10.1182/blood-2023-190978

Published: 2023

Journal Articles

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Chloe Yang, MD, Mina Dehghani, MD, Wilma Hopman, MSc, Sita D. Bhella, MD

Blood (2019) 134 (Supplement_1): 2136.

https://doi.org/10.1182/blood-2019-128819

Published: 2019

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion

Sita D. Bhella, MD, Elizabeth Shin, Marc Poch Martell, MD, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD/PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 1921.

https://doi.org/10.1182/blood.V126.23.1921.1921

Published: 2015

Journal Articles

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Sita D. Bhella, MD, Rumina Musani, MDFCAP, FRCPC, Anna Porwit, MDPhD, Anne Tierens, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 4865.

https://doi.org/10.1182/blood.V126.23.4865.4865

Published: 2015

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

Journal Articles

Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen

Sita D. Bhella, MD, Elizabeth Shin, Marc Poch Martell, MD, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 1948.

https://doi.org/10.1182/blood.V126.23.1948.1948

Published: 2015

Journal Articles

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., Andre C Schuh, MD FRCPC, Mark D Minden, MDPhD, Aaron D Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS, MD, Andrzej Lutynski, MD, Amr Rostom, MD CFPC, Anna Rydlewski, MD, Karen Yee, MD

Blood (2014) 124 (21): 5285.

https://doi.org/10.1182/blood.V124.21.5285.5285

Published: 2014

NARROW

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Are We Choosing Mobilization Regimens for Autologous Stem Cell Transplantation in Multiple Myeloma Wisely?: A Single Centre Comparison of GCSF+/-Plerixafor Vs Cyclophosphamide/GCSF+/- Plerixafor

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only